Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630963 · ClinicalTrials.gov registry record
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
A clinical trial of Major Depressive Disorder, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- 228
- Enrollment target
- 1
- Study location
NCT05630963 is a study of Major Depressive Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 228 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05630963, a study of Major Depressive Disorder, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- 228 participants
- Enrollment target
- 1
- Study location
Study Summary
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Conditions Studied
Interventions
- DEVICE Aversive stimuli
- DRUG PET radiotracer
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2027-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630963
The ClinicalTrials.gov registry entry for NCT05630963 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (39% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Aversive stimuli is the first listed.
NCT05630963 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05630963 about?
NCT05630963 is a clinical study titled "Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression". This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. In...
What is the current status of trial NCT05630963?
This trial is currently recruiting. The enrollment target is 228 participants. The study started on 2021-12-29. Estimated completion is 2027-02-28.
What conditions does trial NCT05630963 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05630963?
The interventions under investigation include: Aversive stimuli (DEVICE), PET radiotracer (DRUG).
Who is sponsoring clinical trial NCT05630963?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05630963 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.